Summit Therapeutics tops up C. diff war chest with $8.8M BARDA funding

C. diff
The U.S. Biomedical Advanced Research and Development Authority can choose to make one last funding boost of $10.1 million, which would bankroll applications for marketing approvals of ridinilazole. (CDC Public Health Image Library/Lois S. Wiggs)

Antibiotics player Summit Therapeutics is gearing up for a new clinical trial of its lead asset, an antibiotic for Clostridium difficile infection, thanks to an $8.8 million cash infusion.  

The $8.8 million brings support from the U.S. Biomedical Advanced Research and Development Authority (BARDA) for the program to a total of $62.4 million, the company said in a statement. It will support a clinical trial of the drug, ridinilazole, in adolescents with C. difficile infection. That study will be part of the new drug application for ridinilazole, as well as “part of a package of work with the potential to provide an additional six months market exclusivity for ridinilazole in the U.S. and Europe,” the company said. 

And there’s more where that came from. BARDA can choose to make one last funding boost of $10.1 million, which would bankroll applications for marketing approvals of the drug. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“BARDA’s continued support for ridinilazole is instrumental in helping to bring this potential CDI treatment option to patients, whose current treatment options fail to sustain cures for one third of the population,” said Summit CEO Glyn Edwards in the statement. 

RELATED: Summit dumps ezutromid after phase 2 Duchenne fail 

C. difficile infection is associated with antibiotic use—broad-spectrum antibiotics throw off the gut microbiome and allow C. difficile bacteria to take over. Paradoxically, in the words of the National Institutes of Health, the current treatments for C. difficile infection are more antibiotics, which cause yet more damage to the microbiome and raise the risk of recurrent infection. Ridinilazole is designed to kill C. difficile while sparing the protective bacteria in patients’ gut. 

In phase 3, ridinilazole is Summit’s most advanced candidate. It has a clutch of earlier-stage programs targeting gonorrhea and hospital-acquired infections, including one aimed at Enterobacteriaceae, a family of bacteria responsible for many severe and often deadly infections of the lung, bloodstream and urinary tract.

Suggested Articles

One day after its Opdivo-paired prospect flopped, Five Prime is farming out some preclinical antibodies to keep its clinical-stage pipeline alive.

U.K.-based surgery robot developer CMR Surgical has begun rolling out its Versius platform to the NHS, completing its first procedures in Europe.

The deal will see GSK pay $50 million and commit to $550 million in milestones for TCRs against two solid tumor targets identified by Immatics.